Literature DB >> 6540867

The use of acyclovir in children.

Y J Bryson.   

Abstract

Acyclovir represents a significant advance in the treatment of herpes simplex and varicella zoster virus infections and appears to be safe and well-tolerated. Physicians now have several drugs to choose from in the treatment of these infections. Hopefully there will be other antiviral chemotherapeutic agents that will be effective for therapy of cytomegalovirus and Epstein-Barr virus infections. Coincident with the development of antivirals, continued progress in the area of rapid viral diagnosis is critical for early institution of therapy. Direct diagnosis of HSV or VZV from clinical specimens or lesions using monoclonal antibodies, enzyme-linked immunoassays or DNA probes are promising techniques for the future. Investigation into improved rapid diagnosis for neonatal and maternal HSV infections and HSV encephalitis should further improve outcome with antiviral therapy.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6540867     DOI: 10.1097/00006454-198407000-00017

Source DB:  PubMed          Journal:  Pediatr Infect Dis        ISSN: 0277-9730


  5 in total

1.  Acyclovir-induced renal failure: course and risk factors.

Authors:  M G Bianchetti; C Roduit; O H Oetliker
Journal:  Pediatr Nephrol       Date:  1991-03       Impact factor: 3.714

2.  Acute kidney injury due to acyclovir.

Authors:  Cigdem Yildiz; Yasemin Ozsurekci; Safak Gucer; Ali Bulent Cengiz; Rezan Topaloglu
Journal:  CEN Case Rep       Date:  2012-10-01

Review 3.  Clinical laboratory applications of monoclonal antibodies.

Authors:  W J Payne; D L Marshall; R K Shockley; W J Martin
Journal:  Clin Microbiol Rev       Date:  1988-07       Impact factor: 26.132

4.  Determinants of aciclovir-induced nephrotoxicity in children.

Authors:  Ruth Schreiber; Jacob Wolpin; Gideon Koren
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

5.  The effect of acyclovir on the tubular secretion of creatinine in vitro.

Authors:  Patrina Gunness; Katarina Aleksa; Gideon Koren
Journal:  J Transl Med       Date:  2010-12-30       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.